ReviewDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
From triggers to interfaces: polymer-stabilized nano-co-crystals for robust mesalazine delivery in UC.
Review in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis profoundly alters the colonic environment, challenging conventional oral drug delivery. Fluctuating luminal pH, irregular transit, mucus remodelling, oxidative stress and microbiota dysbiosis can destabilise trigger-dependent mesalazine formulations and contribute to inconsistent colonic drug exposure.
objectiveThis review examines the mechanistic limitations of trigger-dependent mesalazine delivery and evaluates whether increasing formulation complexity through multi-responsive systems provides sufficient benefit under the heterogeneous and unstable conditions of active ulcerative colitis.
methodsThe review analyses how pathological changes in the colonic environment influence pH-, enzyme- and inflammation-responsive systems and considers polymer-stabilised nano-co-crystal interfacial engineering as a trigger-independent approach. Particular attention is given to crystal engineering and polymer-mediated regulation at the solid-liquid and drug-mucus interfaces.
resultsTrigger-dependent systems rely on pathological cues that vary spatially and temporally during active disease, which can produce variable drug release and colonic exposure. Polymer stabilisation of nano-co-crystals provides an alternative means of controlling drug performance at the formulation interface. Polymer adsorption onto high-energy nano-co-crystal surfaces can stabilise crystalline domains, moderate dissolution, suppress aggregation and recrystallisation, and maintain controlled supersaturation under changing colonic conditions. Polymer functionality may also improve interaction with inflammation-modified mucus, prolong mucosal residence and reduce luminal washout.
conclusionUsing mesalazine as a representative drug, this review reframes colonic delivery in ulcerative colitis as an interface-dominated problem. Polymer-stabilised nano-co-crystals offer a trigger-independent strategy in which drug performance is regulated through crystal and polymer interfaces rather than fluctuating luminal conditions, providing a rational basis for further development of disease-adaptive colonic delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.